E-cigarette and vape uses more prone to infection

Industry InsightInnovation
Jul.22.2022
E-cigarette and vape uses more prone to infection

Rima, a 27-year-old Saudi woman, holds her electronic cigarette as she vapes at a coffee shop in downtown Riyadh, a sign of the changing times in Saudi Arabia - Copyright AFP/File JOHN THYS

Read more: https://www.digitaljournal.com/tech-science/e-cigarette-and-vape-uses-more-prone-to-infection/article#ixzz7ZkXgRHcoUsers of nicotine products are more susceptible to contracting an infection. One research study identified an abundance of Porphyromonas (a genus of Gram-negative bacteria implicated in periodontal disease) and Veillonella (a different group of Gram-negatives associated with cases of osteomyelitis and endocarditis) in higher levels among vapers, suggesting that vaping alters the oral microbiome. The oral microbiome has an established relationship to overall health and it is the second and most diverse microbiota next to the gut, home to over 1,000 species of microbes.

 

Disruptions to this community can lead to health implications. Of particular concern is the bacterium Porphyromonas gingivalis. Enzymes produced by the bacterium can attack collagen.
 

Periodontal, or gum, disease is one of the most common infectious diseases worldwide. In its more severe forms, such as periodontitis, the condition causes loss of the bone that supports the teeth. In addition to gum disease, the bacterium has been linked to rheumatoid arthritis.

 

Ecosystem stability can be affected by two types of disturbances: long-term influences or “presses” and short-term effects or “pulses”. Furthermore, the researchers discovered that interleukin (IL)-6 and IL-1?, a pro-inflammatory cytokines which indicate inflammatory responses, were highly elevated in e-cigarette users when compared with non-users. In particular, epithelial cell-exposed e-cigarette aerosols were more susceptible for infection. This led to the assessment that e-cigarette users are more prone to infection. This occurs because alterations to the microbial landscape, which accompanies higher levels of proteins in vapers’ mouths, signals that the immune system is more likely to activate and produce inflammation. In turn this exponentially increases the likelihood for disease.

 

Additionally, sequencing based studies have shown that certain species of bacteria (Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus and Pseudomonas aeruginosa) are more strongly associated with the development of a
lung community skewed towards loss of diversity. Concerningly, these organisms are associated with declining lung function. It appears that e-cigarette vapor can change the way the bacteria grow, by increasing volume and the area covered by the bacteria, which can lead to infections if untreated.
 

The association between the oral cavity and disease is complex, with the pathogenicity of chronic periodontal disease a factor of the complex interaction of microbial pathogens, host immune response, and genetic and environmental factors. The drawing in of chemical vapor adds to the environmental complexity and appears to be a microbiome altering factor. However, what stands out from research is the general trend that the majority of the metagenome in e-cigarette users was shared by more than the majority of users, which contrasts with smokers and non-smokers, who do not tend to share their bacterial and fungal composition.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
At the 2026 NACS Show, Altria displayed Ploom devices alongside imagery of Marlboro-branded heated tobacco sticks, while also featuring RIOT Energy and Proper Wild non-nicotine products. The booth showcased on! PLUS nicotine pouches, including 12 mg variants not listed among FDA-authorized products as of October 9, and NJOY e-cigarettes. Altria also presented convenience-store traffic figures highlighting its retail presence. 2Firsts examines the company's expanded product portfolio, non-nicotine business activities and the regulatory status of products displayed at the show.
EXPO
Oct.10
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
At InterTabac 2026, nicotine pouch growth was visible not only in brands but across equipment, raw materials and OEM manufacturing. 2Firsts interviewed AIRSCREAM commercial head Steve Moore on how many pouch factories Europe may ultimately need and where manufacturers can differentiate, from formulation and flavour to pouch materials, production consistency and customer service. The category continues to expand, but questions remain over future capacity, consolidation and the long-term structure of the supply chain.
Sep.18
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Japan Tobacco International (JTI) has introduced PERLZ nicotine pearls in the UK, expanding its oral nicotine portfolio beyond conventional nicotine pouches. The fully dissolvable, multi-layer pearls are placed under the tongue and come in Mint and Berry flavors at concentrations of 1mg/g and 2mg/g, equivalent to approximately 0.3mg and 0.5mg of nicotine per pearl. UK retailer Haypp published four 30-pearl dispenser listings on July 31, 2026, followed by three 10-pearl sachet products on August 17. The dispensers retail for £6.50, while the sachets cost £2.50.
product
Oct.12
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
Hawaii's Largest Independent Vape Retailer and Wholesaler Volcano to Close All 13 Stores Ahead of 2027 Sales Rules
Hawaii's Largest Independent Vape Retailer and Wholesaler Volcano to Close All 13 Stores Ahead of 2027 Sales Rules
Hawaii-based vaping company Volcano eCigs plans to close all 13 physical retail stores on December 31, 2026, affecting approximately 56 employees. Volcano operates retail, wholesale, proprietary product and online sales businesses and has previously described itself in legislative testimony as Hawaii's largest independent vape retailer and wholesaler. Its operating company, Jocor Enterprises LLC, filed a formal closure notice on November 4, citing changes in the state's regulatory environment. From January 1, 2027, Hawaii will restrict the sale, acquisition and possession of vaping devices and e-liquids not listed in a state product directory, alongside separate restrictions on certain disposable devices. The closure concerns Volcano's physical retail network; the company has not announced the termination of wholesale or online operations.
Market
Nov.09
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09